243 related articles for article (PubMed ID: 22121999)
21. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Ringold AL; Elliott MA
J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
[TBL] [Abstract][Full Text] [Related]
22. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
Sun TF; Lin PY; Wu CK
Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
[TBL] [Abstract][Full Text] [Related]
23. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
[TBL] [Abstract][Full Text] [Related]
24. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
Sarkar R; Klein J; Krüger S
Psychopharmacology (Berl); 2008 May; 197(4):687-8. PubMed ID: 18264798
[No Abstract] [Full Text] [Related]
25. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
26. A Promising Preliminary Study of Aripiprazole for Treatment-Resistant Childhood Obsessive-Compulsive Disorder.
Ercan ES; Ardic UA; Ercan E; Yuce D; Durak S
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):580-4. PubMed ID: 26375768
[TBL] [Abstract][Full Text] [Related]
27. [Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors].
Arias Horcajadas F; Soto JA; García-Cantalapiedra MJ; Rodríguez Calvin JL; Morales J; Salgado M
Actas Esp Psiquiatr; 2006; 34(3):147-52. PubMed ID: 16736387
[TBL] [Abstract][Full Text] [Related]
28. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
Uzun O; Ozdemir B
Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
[TBL] [Abstract][Full Text] [Related]
29. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
[TBL] [Abstract][Full Text] [Related]
30. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole Augmentation to Mood Stabilizers for Obsessive-Compulsive Symptoms in Bipolar Disorder.
Di Salvo G; Maina G; Pessina E; Teobaldi E; Barbaro F; Martini A; Albert U; Rosso G
Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374357
[No Abstract] [Full Text] [Related]
32. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Brakoulias V; Stockings E
Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
[TBL] [Abstract][Full Text] [Related]
34. Low-dose aripiprazole in the treatment of SSRI-induced bruxism.
Oulis P; Dimitrakopoulos S; Konstantakopoulos G; Tsaltas E; Kollias K
J Neuropsychiatry Clin Neurosci; 2012; 24(3):E39. PubMed ID: 23037677
[No Abstract] [Full Text] [Related]
35. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
36. A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.
Dar SA; Wani RA; Haq I
Psychiatr Q; 2021 Dec; 92(4):1413-1424. PubMed ID: 33830427
[TBL] [Abstract][Full Text] [Related]
37. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
Metin O; Yazici K; Tot S; Yazici AE
Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825
[TBL] [Abstract][Full Text] [Related]
38. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
[TBL] [Abstract][Full Text] [Related]
39. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
[TBL] [Abstract][Full Text] [Related]
40. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Dold M; Aigner M; Lanzenberger R; Kasper S
Int J Neuropsychopharmacol; 2013 Apr; 16(3):557-74. PubMed ID: 22932229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
